Bococizumab (Acute Coronary Syndrome) Clinical Trials Review 2016 By Global Market Research Store

Bococizumab (Acute Coronary Syndrome) - Forecast and Market Analysis to 2023

Market Research Store has released its new PharmaPoint Drug Evaluation report, Bococizumab (Acute Coronary Syndrome) Forecast and Market Analysis to 2023. The current ACS market primarily comprised of antithrombotics, antihypertensives, and statins is flush with well-established standard-of-care therapies, many of which are generic. Therefore, the pipeline therapies that show the most promise exploit novel mechanisms of action and target orphan biochemical pathways. The ACS market will be driven by an aging population with a preponderance of lifestyle-based diseases, such as obesity, and the growing prevalence of metabolic disorders such as diabetes. The expansion of biologics into the ACS mainstream during the ten year forecast period is expected to significantly and fundamentally alter the ACS market, both medically and financially.

Read Complete Report with TOC: http://goo.gl/YyECb5

Analyst anticipates that Pfizers PCSK9 mAb, bococizumab (PF-04950615), will be the third-to-market PCSK9 inhibitor behind Amgens evolocumab and Sanofi and Regenerons alirocumab, which GlobalData expects are first and second in line for US regulatory approval, respectively. Similar to these other PCSK9 inhibitors, bococizumab is heading into Phase III studies with positive Phase II dosing and LDL-C lowering results. A novel set of LDL-C drugs, proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors reduce levels of LDL-C by enhancing the livers ability to filter LDL-C particles from the circulation.

Scope

Overview of ACS, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
Detailed information on Aricept including product description, safety and efficacy profiles as well as a SWOT analysis.
Sales forecast for Aricept for the top seven countries from 2013 to 2023.
Sales information covered for the US, France, Germany, Italy, Spain, the UK and Japan.

Reasons to buy

Understand and capitalize by identifying products that are most likely to ensure a robust return
Stay ahead of the competition by understanding the changing competitive landscape for ACS
Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
Make more informed business decisions from insightful and in-depth analysis of Aricept performance
Obtain sales forecast for Aricept from 2013-2023 in top seven countries (the US, France, Germany, Italy, Spain, the UK and Japan)

Get Sample Copy of Report: http://goo.gl/r7c7Bb

Table of Contents

1 Table of Contents 6
1.1 List of Tables 9
1.2 List of Figures 10

2 Introduction 11
2.1 Catalyst 11
2.2 Related Reports 12
2.3 Upcoming Related Reports 14

3 Disease Overview 15
3.1 Etiology and Pathophysiology 16
3.1.1 Etiology 16
3.1.2 Pathophysiology 20
3.1.3 Prognosis 21
3.1.4 Quality of Life 22
3.2 Symptoms 22

About Us:

Market Research Store is a single destination for all the industry, company and country reports. We feature large repository of latest industry reports, leading and niche company profiles, and market statistics released by reputed private publishers and public organizations.

Contact Us:

Joel John
Deerfield Beach, Florida 33442
United States
Toll Free: +1-855-465-4651 (USA-CANADA)
Tel: +1-386-310-3803
Web: Market Research Store
Email: sales@marketresearchstore.com

This release was published on openPR.